NIBEC CO., LTD. Logo

NIBEC CO., LTD.

Biotech CDMO creating regenerative products with peptide and biomaterial technologies.

138610 | KO

Overview

Corporate Details

ISIN(s):
KR7138610001
LEI:
Country:
South Korea
Address:
충청북도 진천군 이월면 밤디길 116 이월전기전자농공1단지, 진천군
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NIBEC Co., Ltd. is a biotechnology company focused on developing innovative healthcare solutions through regenerative medicine. The company specializes in the research, development, and commercialization of products based on its core expertise in bioactive peptide technology and advanced biomaterials. Its primary offerings include tissue regenerative products, such as dental bone grafts and collagen-based materials, as well as peptide-based smart materials and bio-fusion products for medical applications. Additionally, NIBEC operates as a Contract Development and Manufacturing Organization (CDMO), providing cGMP-compliant custom peptide synthesis and manufacturing services to the pharmaceutical and biotech sectors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 903.3 KB
2025-08-14 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-06-04 00:00
Share Issue/Capital Change
전환청구권행사
Korean 11.5 KB
2025-05-28 00:00
M&A Activity
투자판단관련주요경영사항 (NP201 기술이전의 건)
Korean 13.8 KB
2025-05-22 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.1 KB
2025-05-22 00:00
Share Issue/Capital Change
전환가액의조정
Korean 12.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 815.7 KB
2025-04-09 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.2 KB
2025-03-20 00:00
Annual Report
사업보고서 (2024.12)
Korean 993.7 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 18.1 KB
2025-03-20 00:00
Audit Report / Information
[기재정정]감사보고서제출
Korean 21.2 KB
2025-03-10 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 101.6 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 92.6 KB

Automate Your Workflow. Get a real-time feed of all NIBEC CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NIBEC CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NIBEC CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.